BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended March 31, 2008
Business Overview: BD is a medical technology company operating through three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 11% year-over-year for the quarter and 12% for the six-month period. Growth was driven by volume increases (~6%), favorable foreign currency translation (~5%), and partially offset by price decreases (~0.5%).
• Segment Performance:
  • Medical: Revenues up 9% (quarter) and 10% (six months). Operating income margin decreased slightly to 27.2% due to raw material costs and inventory write-offs.
  • Diagnostics: Revenues up 12% (quarter) and 15% (six months). Operating income improved significantly compared to the prior year, which included a $114.7 million charge for acquired in-process R&D related to the TriPath acquisition.
  • Biosciences: Revenues up 14% (quarter) and 16% (six months). Operating income margin improved to 28.6%.
• Profitability: Net income increased 14% for the quarter and 42% for the six-month period. The six-month comparison is favorable due to the absence of the prior year's TriPath acquisition charge.
• Cost Pressures: Gross profit margins declined slightly due to increased costs of raw materials (primarily resins), manufacturing start-up costs, and asset write-offs.

Guidance, Outlook, and Risks

• Margin Outlook: Management expects gross profit margins to decrease by 30 to 40 basis points in 2008 compared to 2007 due to raw material costs and write-offs. Selling and administrative expenses are expected to decrease by about 80 basis points as a percentage of revenue.
• Expense Outlook: Research and development expenses are anticipated to increase by approximately 11% in 2008. Capital spending is expected to be around $650 million for the full year.
• Tax Rate: The reported tax rate for 2008 is expected to be approximately 27.5%.
• Legal Contingencies:
  • Antitrust: BD is a defendant in multiple class action suits alleging violations of federal antitrust laws regarding product pricing. These are consolidated in Multi-District Litigation (MDL).
  • Patent Litigation: Retractable Technologies, Inc. (RTI) has filed patent infringement claims regarding BD Integra syringes. A trial is scheduled for March 2009.
  • Product Liability: Pending needlestick class actions and latex glove liability suits (though most latex cases have been closed or settled).
  • Regulatory: Ongoing investigations by the French Judicial Police regarding the UN Oil-for-Food Programme and subpoenas from Connecticut and Illinois regarding HRDI participation.
• Market Risks: Exposure to foreign currency fluctuations, raw material costs (oil-based resins), and healthcare industry pricing pressures.

Investor Verification Checklist

• Raw Material Costs: Verify the sustainability of resin price increases and their impact on future gross margins.
• Legal Exposure: Monitor the status of the RTI patent trial (scheduled March 2009) and the consolidated antitrust MDL proceedings.
• Currency Impact: Assess the sensitivity of future earnings to foreign exchange rate fluctuations, which provided a favorable ~5% impact in this period.
• Capital Allocation: Review the $276 million in stock repurchases and the remaining $7.9 million share authorization against future cash flow needs.
• Segment Mix: Confirm the continued growth trajectory of the Diagnostics segment, particularly the TriPath product line integration.